How Eye-Preserving Therapy Affects Long-Term Overall Survival in Heritable Retinoblastoma Survivors [Pediatric Oncology]
Conclusion
The benefits of preserving vision must be balanced with the impact of eye-preserving treatments on long-term survival in heritable retinoblastoma, and the genetic background of the patient influences choice of eye-preserving treatment. Germline RB1 genetic analysis is important to identify heritable retinoblastoma among unilateral retinoblastoma cases. Eye-preserving radiotherapy should be carefully considered in patients with germline RB1 mutations. Life-long oncologic follow-up is crucial for all retinoblastoma survivors, and less detrimental eye-preserving therapies must be developed. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Temming, Arendt, Viehmann, Eisele, Le Guin, Schundeln, Biewald, Mausert, Wieland, Bornfeld, Sauerwein, Eggert, Lohmann, Jockel Tags: Genetic epidemiology, Population and observational studies (SEER, WHI observational, etc.), Radiation, Chemotherapy, Retinoblastoma, Epidemiology, Osteosarcoma, Retinoblastoma, Rhabdomyosarcoma & Soft Tissue Sarcoma, Long Term Survival & Late Effects, Rad Source Type: research
Choice of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study [Thoracic Oncology]
Conclusion
Lobectomy showed better survival than sublobar resection for patients with NSCLC ≤ 1 cm and > 1 to 2 cm. For patients in whom lobectomy is unsuitable, segmentectomy should be recommended for NSCLC > 1 to 2 cm, whereas surgeons could rely on surgical skills and the patient profile to decide between segmentectomy and wedge resection for NSCLC ≤ 1 cm. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Dai, Shen, Ren, Zhong, Zheng, He, Xie, Fei, Liang, Jiang, Yang, Petersen, Ng, Liu, Rocco, Brunelli, Shen, Chen, He Tags: Surgical Oncology, Surgery Thoracic Oncology Source Type: research
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma [Sarcomas]
Conclusion
Selinexor was well tolerated at a 60-mg flat dose on a 3-weeks-on, 1-week-off schedule. There was no clinically meaningful impact of food on PKs. Preliminary evidence of anticancer activity in sarcoma was demonstrated. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Gounder, Zer, Tap, Salah, Dickson, Gupta, Keohan, Loong, DAngelo, Baker, Condy, Nyquist-Schultz, Tanner, Erinjeri, Jasmine, Friedlander, Carlson, Unger, Saint-Martin, Rashal, Ellis, Kauffman, Shacham, Schwartz, Abdul Razak Tags: Phase I and Clinical Pharmacology, Osteosarcoma & Ewing Sarcomas:, Rhabdo & Other Soft Tissue Sarcomas: Source Type: research
Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis [Breast Cancer]
Conclusion
Our findings in a largely unadjusted analysis suggest that overweight and obesity are risk factors for cardiotoxicity from anthracyclines and sequential anthracyclines and trastuzumab. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Guenancia, Lefebvre, Cardinale, Yu, Ladoire, Ghiringhelli, Zeller, Rochette, Cottin, Vergely Tags: Chemotherapy Breast Cancer Source Type: research
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP [Hematologic Malignancy]
Conclusion
The CNS-IPI is a robust, highly reproducible tool that can be used to estimate the risk of CNS relapse/progression in patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. Close to 90% of patients with DLBCL belong to the low- and intermediate-risk groups and have a CNS relapse risk < 5%; they may be spared any diagnostic and therapeutic intervention. In contrast, those in the high-risk group have a > 10% risk of CNS relapse and should be considered for CNS-directed investigations and prophylactic interventions. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Schmitz, Zeynalova, Nickelsen, Kansara, Villa, Sehn, Glass, Scott, Gascoyne, Connors, Ziepert, Pfreundschuh, Loeffler, Savage Tags: Prognostic Studies, Chemotherapy Hematologic Malignancy Source Type: research
Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis [Hematologic Malignancy]
Conclusion
Haplo-HCT with PT-Cy provides survival outcomes comparable to MSD-HCT, with a significantly lower risk of chronic GVHD. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Ghosh, Karmali, Rocha, Ahn, DiGilio, Hari, Bachanova, Bacher, Dahi, de Lima, DSouza, Fenske, Ganguly, Kharfan-Dabaja, Prestidge, Savani, Smith, Sureda, Waller, Jaglowski, Herrera, Armand, Salit, Wagner-Johnston, Fuchs, Bolanos-Meade, Hamadani Tags: Lymphoma Hematologic Malignancy Source Type: research
Trends in Obesity Prevalence in Adults With a History of Cancer: Results From the US National Health Interview Survey, 1997 to 2014 [Epidemiology]
Conclusion
From 1997 to 2014, obesity increased more rapidly among adult cancer survivors compared with the general population. Colorectal and breast cancer survivors and non-Hispanic blacks were identified as being at the highest risk for obesity. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Greenlee, Shi, Sardo Molmenti, Rundle, Tsai Tags: Behavioral and Lifestyle Risk Factors, Population and observational studies (SEER, WHI observational, etc.) Epidemiology Source Type: research
Barriers to Quality End-of-Life Care for Patients With Blood Cancers [Health Services and Outcomes]
Conclusion
In this large national cohort of hematologic oncologists, standard EOL quality measures were highly acceptable. The top barrier to quality EOL care reported was unrealistic patient expectations, which may be best addressed with more timely and effective advance care discussions. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Odejide, Cronin, Condron, Fletcher, Earle, Tulsky, Abel Tags: Quality of Care, End of Life, Outcomes Research, Quality of Care, Palliative Care Health Services and Outcomes Source Type: research
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer [Rapid Communication]
Conclusion
Durvalumab demonstrated a manageable safety profile and evidence of meaningful clinical activity in PD-L1–positive patients with UBC, many of whom were heavily pretreated. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Massard, Gordon, Sharma, Rafii, Wainberg, Luke, Curiel, Colon-Otero, Hamid, Sanborn, ODonnell, Drakaki, Tan, Kurland, Rebelatto, Jin, Blake-Haskins, Gupta, Segal Tags: Phase I and Clinical Pharmacology, Translational Oncology, Rapid Communications, Rapid Communications, Other, Phase I and Clinical Pharmacology Source Type: research
Evaluating Quality Metrics for the Care of Patients With Blood Cancer Who Are Near Death [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Trevino, Martin, Prigerson Tags: Leukemia, Lymphoma, End of Life EDITORIALS Source Type: research
Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Drake, Bivalacqua, Hahn Tags: Translational Oncology, Immunology/Immunobiology EDITORIALS Source Type: research
Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research
Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research
Reply to J. Nudelman [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Asdourian, Skolny, Brunelle, Seward, Salama, Taghian Tags: CORRESPONDENCE Source Type: research
Reply to A. Gomberawalla et al and J. Nudelman [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Ahn, Port Tags: CORRESPONDENCE Source Type: research
